Your browser doesn't support javascript.
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
Vallejos, Julio; Zoni, Rodrigo; Bangher, María; Villamandos, Silvina; Bobadilla, Angelina; Plano, Fabian; Campias, Claudia; Chaparro Campias, Evangelina; Medina, Maria Fernanda; Achinelli, Fernando; Guglielmone, Hector Andres; Ojeda, Jorge; Farizano Salazar, Diego; Andino, Gerardo; Kawerin, Pablo; Dellamea, Silvana; Aquino, Antonia Cristina; Flores, Victor; Martemucci, Carolina N; Martinez, Silvina Maria; Segovia, Juan Emanuel; Reynoso, Paola Itati; Sosa, Noelia Carolina; Robledo, Mariana Elizabeth; Guarrochena, Joaquina Maria; Vernengo, Maria Mercedes; Ruiz Diaz, Natalia; Meza, Elba; Aguirre, María Gabriela.
  • Vallejos J; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
  • Zoni R; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina. rodrizoni@yahoo.com.ar.
  • Bangher M; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
  • Villamandos S; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
  • Bobadilla A; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Plano F; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
  • Campias C; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Chaparro Campias E; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Medina MF; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
  • Achinelli F; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
  • Guglielmone HA; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Ojeda J; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
  • Farizano Salazar D; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
  • Andino G; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Kawerin P; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Dellamea S; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
  • Aquino AC; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
  • Flores V; Hospital de Campaña, Ministerio de Salud Pública de la Provincia de Corrientes, Ministerio de Salud Pública de Corrientes, Corrientes, Argentina.
  • Martemucci CN; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Martinez SM; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Segovia JE; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Reynoso PI; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
  • Sosa NC; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
  • Robledo ME; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
  • Vernengo MM; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Ruiz Diaz N; Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Meza E; Epidemiology. Ministerio de Salud Pública de la Provincia de Corrientes, Corrientes, Argentina.
  • Aguirre MG; Instituto de Cardiología de Corrientes, Bolivar 1334, Zip code, 3400, Corrientes, Argentina.
BMC Infect Dis ; 21(1): 635, 2021 Jul 02.
Article in English | MEDLINE | ID: covidwho-1295445
ABSTRACT

BACKGROUND:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients.

OBJECTIVE:

To determine whether ivermectin treatment can prevent hospitalization in individuals with early COVID-19. DESIGN, SETTING AND

PARTICIPANTS:

A randomized, double-blind, placebo-controlled study was conducted in non-hospitalized individuals with COVID-19 in Corrientes, Argentina. Patients with SARS-CoV-2 positive nasal swabs were contacted within 48 h by telephone to invite them to participate. The trial randomized 501 patients between August 19th 2020 and February 22nd 2021. INTERVENTION Patients were randomized to ivermectin (N = 250) or placebo (N = 251) arms in a staggered dose, according to the patient's weight, for 2 days. MAIN OUTCOMES AND

MEASURES:

The efficacy of ivermectin to prevent hospitalizations was evaluated as primary outcome. We evaluated secondary outcomes in relationship to safety and other efficacy end points.

RESULTS:

The mean age was 42 years (SD ± 15.5) and the median time since symptom onset to the inclusion was 4 days [interquartile range 3-6]. The primary outcome of hospitalization was met in 14/250 (5.6%) individuals in ivermectin group and 21/251 (8.4%) in placebo group (odds ratio 0.65; 95% confidence interval, 0.32-1.31; p = 0.227). Time to hospitalization was not statistically different between groups. The mean time from study enrollment to invasive mechanical ventilatory support (MVS) was 5.25 days (SD ± 1.71) in ivermectin group and 10 days (SD ± 2) in placebo group, (p = 0.019). There were no statistically significant differences in the other secondary outcomes including polymerase chain reaction test negativity and safety outcomes.

LIMITATIONS:

Low percentage of hospitalization events, dose of ivermectin and not including only high-risk population.

CONCLUSION:

Ivermectin had no significant effect on preventing hospitalization of patients with COVID-19. Patients who received ivermectin required invasive MVS earlier in their treatment. No significant differences were observed in any of the other secondary outcomes. TRIAL REGISTRATION ClinicalTrials.gov NCT04529525 .
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ivermectin / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: S12879-021-06348-5

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Ivermectin / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Topics: Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: BMC Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: S12879-021-06348-5